Recent findings from a small, proof-of-concept clinical trial have shed light on the potential of fecal microbiota transplants (FMTs) to improve the effectiveness of immunotherapy in treating various gastrointestinal cancers. Published on July 25 in Cell Host & Microbe, the study reveals promising outcomes for patients who had previously shown resistance to immune checkpoint inhibitors.
The trial involved 13 patients with advanced solid-tumor cancers, such as gastric, esophageal, and hepatocellular carcinoma, who had not responded to the anti-PD-1 drug nivolumab. Six of these patients benefited from FMTs received from donors who had previously responded well to similar treatments. The researchers identified specific bacterial strains that appeared to either enhance or hinder the success of FMT and immune checkpoint therapy, highlighting the intricate relationship between gut microbiota and treatment outcomes.
Dr. Hansoo Park from the Gwangju Institute of Science and Technology in South Korea emphasized the significance of these findings, noting that while the connection between gut microbiota and cancer treatment has been explored before, this study provides concrete evidence and opens new avenues for improving treatment across a wider range of cancers.
Immune checkpoint inhibitors have transformed cancer treatment, yet many patients either do not respond or eventually develop resistance. Previous studies had shown that FMTs could overcome such resistance in melanoma patients, but this study is the first to demonstrate its potential in other advanced solid tumors.
One of the most surprising results came from a hepatocellular carcinoma patient who initially did not respond to the first FMT and continued to experience disease progression. However, after receiving a second FMT from a different donor, the patient’s tumors began to shrink significantly. This unexpected outcome underscores the complexity of the gut microbiota’s role in cancer treatment, as even donors with similar clinical histories can produce different results.
The researchers identified a new bacterial strain, Prevotella merdae Immunoactis, which appeared to enhance FMT efficacy, along with two strains, Lactobacillus salivarius and Bacteroides plebeius, that negatively impacted the treatment. These discoveries pave the way for future studies aimed at developing strategies to modify the gut microbiota and boost the effectiveness of immunotherapy.
Despite the promising results, the researchers acknowledge the challenges of integrating FMT into standard cancer treatment. Issues such as the lack of standardized protocols, the risk of pathogen transmission, and logistical hurdles in producing and distributing FMT products on a large scale need to be addressed.
Dr. Sook Ryun Park from Asan Medical Center at the University of Ulsan College of Medicine in Seoul highlights the importance of developing efficient and cost-effective methods for FMT production and distribution to enable widespread adoption. Comprehensive research and careful planning will be essential in overcoming these challenges and making FMT a viable part of cancer treatment in the future.
This study represents a significant step forward in understanding how the gut microbiota can be harnessed to improve cancer treatment outcomes. By continuing to explore the complex interactions within the microbiome, researchers hope to unlock new strategies for enhancing the effectiveness of immunotherapy, potentially transforming the standard of care for patients with gastrointestinal cancers.
Reference: Yunjae Kim, Gihyeon Kim, Sujeong Kim, Beomki Cho, Sang-Yeob Kim, Eun-Ju Do, Dong-Jun Bae, Seungil Kim, Mi-Na Kweon, Joon Seon Song, Sang Hyoung Park, Sung Wook Hwang, Mi-Na Kim, Yeongmin Kim, Kyungchan Min, Sung-Han Kim, Mark D. Adams, Charles Lee, Hansoo Park, Sook Ryun Park. (25 July 2024). Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2024.06.010
